Montserrat Alegret
Overview
Explore the profile of Montserrat Alegret including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
3052
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garcia-Gutierrez F, Alegret M, Marquie M, Munoz N, Ortega G, Cano A, et al.
Alzheimers Res Ther
. 2024 Feb;
16(1):26.
PMID: 38308366
Background: Advancement in screening tools accessible to the general population for the early detection of Alzheimer's disease (AD) and prediction of its progression is essential for achieving timely therapeutic interventions...
12.
Alegret M, Garcia-Gutierrez F, Munoz N, Espinosa A, Ortega G, Lleonart N, et al.
J Alzheimers Dis
. 2024 Jan;
97(3):1173-1187.
PMID: 38217602
Background: The FACEmemory® online platform comprises a complex memory test and sociodemographic, medical, and family questions. This is the first study of a completely self-administered memory test with voice recognition,...
13.
Garcia-Gutierrez F, Marquie M, Munoz N, Alegret M, Cano A, de Rojas I, et al.
Front Neurosci
. 2023 Sep;
17:1221401.
PMID: 37746151
Alzheimer's disease (AD) is a neurodegenerative condition characterized by a gradual decline in cognitive functions. Currently, there are no effective treatments for AD, underscoring the importance of identifying individuals in...
14.
Morato X, Marquie M, Tartari J, Lafuente A, Abdelnour C, Alegret M, et al.
Sci Rep
. 2023 Apr;
13(1):5406.
PMID: 37012306
Although beta-amyloid (Aβ) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer's disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation...
15.
Marquie M, Garcia-Sanchez A, Alarcon-Martin E, Martinez J, Castilla-Marti M, Castilla-Marti L, et al.
Front Neurosci
. 2023 Mar;
17:1076177.
PMID: 36908784
Background: Optical coherence tomography angiography (OCT-A) is a novel method in the dementia field that allows the detection of retinal vascular changes. The comparison of OCT-A measures with established Alzheimer's...
16.
Cano A, Esteban-de-Antonio E, Bernuz M, Puerta R, Garcia-Gonzalez P, de Rojas I, et al.
J Nanobiotechnology
. 2023 Feb;
21(1):54.
PMID: 36788617
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of...
17.
de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen I, et al.
Nat Commun
. 2023 Feb;
14(1):716.
PMID: 36759603
No abstract available.
18.
Marquie M, Garcia-Gutierrez F, Orellana A, Montrreal L, de Rojas I, Garcia-Gonzalez P, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36674881
Few studies have addressed the impact of the association between Alzheimer's disease (AD) biomarkers and NPSs in the conversion to dementia in patients with mild cognitive impairment (MCI), and no...
19.
Marquie M, Valero S, Martinez J, Alarcon-Martin E, Garcia-Sanchez A, de Rojas I, et al.
Sci Rep
. 2022 Oct;
12(1):16938.
PMID: 36209290
Optical coherence tomography angiography (OCT-A) allows the detection of retinal vessel density (VD) loss, which is a reflection of brain vascular pathology. We aimed to investigate differences in macular VD...
20.
Jansen I, van der Lee S, Gomez-Fonseca D, de Rojas I, Dalmasso M, Grenier-Boley B, et al.
Acta Neuropathol
. 2022 Sep;
144(5):821-842.
PMID: 36066633
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the...